Current treatment options for relapsed CLL
The management of relapsed chronic lymphocytic leukemia (CLL) is a complex and difficult issue. We interviewed William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, on the subject at...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Genetic screening to inform CLL treatment
Biomarker screening has become an essential component of constructing treatment plans in chronic lymphocytic leukemia (CLL). In this video, recorded at the 23rd Congress of the European Hematology Ass...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Incorporating novel therapies into frontline ALL treatment
Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research. Here, Oliver Ottmann, MD, FRCPath, of Cardiff Univer...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Targeting CD123 to treat myelofibrosis and CMML
Overexpression of CD123 is associated with a number of hematological malignancies, including myelofibrosis and chronic myelomonocytic leukemia (CMML). Data was presented at the 23rd Congress of the Eu...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel agent combinations: the future of CLL
There has been an influx of novel agents in the field of chronic lymphocytic leukemia (CLL) in recent years. These include venetoclax, ibrutinib and obinutuzumab. In this video, recorded at the 23rd C...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
BCL-2 inhibitors: the current landscape
BCL-2 inhibitors like ibrutinib and venetoclax have been used in the treatment of lymphoproliferative disorders like chronic lymphocytic leukemia (CLL) for long enough that mid-term effects of the age...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
ZUMA-3 update: prior blinatumomab does not alter CAR T-cell efficacy in ALL
There are promising results from a variety of studies implicating CAR T-cells in relapsed/refractory acute lymphoblastic leukemia (ALL) treatment. Here, William Wierda, MD, PhD, of the MD Anderson Can...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel agents in CLL: the current landscape
The development of novel agents for treating chronic lymphocytic leukemia (CLL) has transformed the field in recent years. In this video, recorded at the 23rd Congress of the European Hematology Assoc...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
The future of inotuzumab therapy for ALL
Inotuzumab ozogamicin has shown extremely promising results in clinical trials for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). There are, however, still issues with legislatio...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel agents in AML: highlights from EHA 2018
The development of novel agents to treat acute myeloid leukemia (AML) is constantly revolutionizing the field. In this video, Christoph Rllig, MD, of the University Hospital Carl Gustav Carus, Dresde...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Defining ALL risk factors: the prognostic index
We should move away from using risk factors as individual binary variables within acute lymphoblastic leukemia (ALL) research, suggests Anthony Moorman, PhD, of Newcastle University, Newcastle, UK, at...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
TKIs in CLL: an overview
The use of tyrosine kinase inhibitors (TKIs) in chronic lymphocytic leukemia (CLL) is expanding. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Obinutuzumab increases survival in CLL patients with comorbidities
The CLL11 trial (NCT01998880) compared chlorambucil monotherapy with combination therapies of chlorambucil and anti-CD20 antibodies rituximab or obinutuzumab for chronic lymphocytic leukemia (CLL) in ...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
CAPTIVATE and beyond: combination therapies for CLL
Novel agent combination therapies are coming to the forefront of chronic lymphocytic leukemia (CLL) research. Here, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses a ...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Pulmonary infiltration of CLL: implications for treatment
In chronic lymphocytic leukemia (CLL), treatment is often delayed because patients develop infections. Florence Cymbalista, PhD, from the Hpital Avicenne, Bobigny, France, presented results at the 23...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
